Unit
- Origins of methadone maintenance: Developed in the 1960s by Drs. Vincent Dole and Marie Nyswander as a long-term treatment for opioid addiction. It shifted the paradigm from abstinence-only to medically supervised maintenance, reducing illicit opioid use and crime. The approach is now recognized by the World Health Organization as an essential medicine.
- Pharmacodynamic action: Methadone acts as a full mu-opioid receptor agonist with a long half-life of 24-36 hours, preventing withdrawal symptoms and reducing cravings without producing euphoria at stable doses. This property allows once-daily oral administration, making it practical for outpatient programs.
- Absorption and metabolism: Orally administered methadone is well absorbed with peak plasma concentrations occurring within 2-4 hours. It undergoes extensive hepatic metabolism via CYP3A4 and CYP2D6 enzymes, with interindividual variability requiring careful dose titration.
- Tolerance and cross-tolerance: Chronic use produces tolerance to opioid effects, requiring gradual dose increases during induction. Methadone exhibits complete cross-tolerance with other opioids, so patients cannot obtain additional effects from illicit heroin or prescription opioids while on an adequate dose.
- QT interval prolongation risk: High doses of methadone can prolong the cardiac QT interval, increasing the risk of torsade de pointes. Baseline and follow-up electrocardiograms are recommended for patients on doses above 120 mg/day or those with other risk factors.
- Withdrawal management: Methadone prevents acute withdrawal symptoms for 24-36 hours due to its long half-life. Abrupt discontinuation can lead to protracted withdrawal lasting weeks. Therefore, tapering protocols are essential for patients transitioning off treatment.
- Research supporting effectiveness: Studies consistently show that methadone maintenance reduces opioid use, injection-related infections, overdose deaths, and criminal activity. Retention in treatment is higher compared to abstinence-based approaches, particularly when combined with psychosocial support.
- Contraindications and precautions: Methadone is contraindicated in patients with known hypersensitivity, severe respiratory depression, or concurrent use of MAO inhibitors. Caution is needed in patients with liver disease, respiratory conditions, or head injuries.
- Induction phase and dose titration: Treatment typically begins with a starting dose of 20 to 30 mg daily, with gradual increases of 5 to 10 mg every few days. This cautious approach minimizes the risk of respiratory depression while preventing withdrawal symptoms. The stabilization process usually requires one to three weeks, after which a maintenance dose is established.
- Methadone in pregnancy: Methadone maintenance is the recommended standard of care for pregnant individuals with opioid use disorder. It prevents maternal withdrawal and reduces fetal harm, though dose adjustments may be needed due to increased metabolism and plasma volume. Neonates may experience withdrawal, which is managed with supportive care or medication.
- Drug interactions: Methadone metabolism is affected by CYP3A4 inducers such as rifampin and carbamazepine, which lower methadone levels and may trigger withdrawal. Conversely, CYP3A4 inhibitors like fluconazole and certain SSRIs can raise methadone levels, increasing sedation and respiratory depression risk. Concurrent use of CNS depressants like alcohol or benzodiazepines requires extreme caution.
- Take home dosing policies: Patients who demonstrate stable adherence, negative urine drug screens, and no evidence of diversion may qualify for take home doses. This reduces daily clinic visits and supports reintegration into work and family life. Federal and state regulations define eligibility criteria and maximum amounts, balancing clinical benefit with safety monitoring.
Terminology
- Full mu-opioid receptor agonist
- A substance that binds to and activates mu-opioid receptors in the brain, producing effects such as pain relief and euphoria at high doses, but with a ceiling effect for respiratory depression.
- Half-life
- The time required for the plasma concentration of a drug to decrease by 50%, influencing dosing frequency and withdrawal onset.
- CYP3A4 and CYP2D6
- Enzymes in the liver responsible for metabolizing many drugs, including methadone; genetic variants affect metabolism rates.
Quick Revision
- Methadone maintenance was pioneered in the 1960s as a long-term opioid agonist therapy.
- Its long half-life allows once-daily oral dosing, stabilizing patients and reducing cravings.
- Metabolism varies by individual, requiring careful dose titration.
- QT prolongation is a risk at high doses, necessitating ECG monitoring.
- Abrupt cessation can cause prolonged withdrawal, so tapering is essential.